These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 38136770)

  • 1. Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing
    Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2023 Dec; 12(12):. PubMed ID: 38136770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin-Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing
    Gatti M; Bonazzetti C; Pascale R; Giannella M; Viale P; Pea F
    Microorganisms; 2024 Jan; 12(1):. PubMed ID: 38257978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP.
    Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2024 Mar; 13(4):. PubMed ID: 38666972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections.
    Gatti M; Rinaldi M; Laici C; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections.
    Berrino PM; Gatti M; Rinaldi M; Brunocilla E; Viale P; Pea F
    Antibiotics (Basel); 2023 Aug; 12(9):. PubMed ID: 37760685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration.
    Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2023 Oct; 12(10):. PubMed ID: 37887225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia.
    Gatti M; Pascale R; Cojutti PG; Rinaldi M; Ambretti S; Conti M; Tedeschi S; Giannella M; Viale P; Pea F
    Int J Antimicrob Agents; 2023 Jan; 61(1):106699. PubMed ID: 36464151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections.
    Gatti M; Campoli C; Latrofa ME; Ramirez S; Sasso T; Mancini R; Caramelli F; Viale P; Pea F
    Pediatr Infect Dis J; 2023 Nov; 42(11):975-982. PubMed ID: 37523585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?
    Gatti M; Rinaldi M; Bonazzetti C; Gaibani P; Giannella M; Viale P; Pea F
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0096923. PubMed ID: 37843260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant
    Gatti M; Giannella M; Rinaldi M; Gaibani P; Viale P; Pea F
    Antibiotics (Basel); 2022 Dec; 11(12):. PubMed ID: 36551398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol.
    Gatti M; Bartoletti M; Cojutti PG; Gaibani P; Conti M; Giannella M; Viale P; Pea F
    J Glob Antimicrob Resist; 2021 Dec; 27():294-298. PubMed ID: 34710630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections.
    Gatti M; Cojutti PG; Pascale R; Tonetti T; Laici C; Dell'Olio A; Siniscalchi A; Giannella M; Viale P; Pea F
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem.
    Sanz Codina M; Gatti M; Troisi C; Fornaro G; Pasquini Z; Trapani F; Zanoni A; Caramelli F; Viale P; Pea F
    Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients.
    Cojutti PG; Pai MP; Gatti M; Rinaldi M; Ambretti S; Viale P; Pea F
    J Antimicrob Chemother; 2024 Nov; 79(11):2801-2808. PubMed ID: 39159014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis.
    Gatti M; Tedeschi S; Trapani F; Ramirez S; Mancini R; Giannella M; Viale P; Pea F
    Antibiotics (Basel); 2022 Aug; 11(8):. PubMed ID: 36009906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
    Cojutti PG; Morandin E; Baraldo M; Pea F
    Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF).
    Gatti M; Rinaldi M; Tonetti T; Gaibani P; Siniscalchi A; Viale P; Pea F
    Int J Antimicrob Agents; 2023 Aug; 62(2):106852. PubMed ID: 37192727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.